The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input fro | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.

Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.

New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved anti-obesity medications.

CMS said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.

The Centers for Medicare & Medicaid Services (CMS) finalized significant updates to the Medicare 60-Day Rule, which governs how providers

Healthcare Management Solutions LLC can perform a $41 million auditing services task order for the Centers of Medicare and Medicaid Services despite the agency’s improper discussions, the US Court of Federal Claims said.

An expanding prohibition on third-party financial guarantees could lead to more nursing home using lawsuits to collect unpaid debt.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,

CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most dramatic drops in scores. In its lawsuit, the UnitedHealth Group subsidiary alleged the decline improperly cost the company “tens of millions” in federal payments.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

The Increasing Organ Transplant Access Model ("IOTA Model") introduces mandatory financial incentives and penalties for selected kidney